Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer

Systemic treatment of advanced pancreatic cancer

(2012) Volker Heinemann et al.   CANCER TREATMENT REVIEWS

Pancreatic cancer treatment and research: an international expert panel discussion

(2011) M. A. Tempero et al.   ANNALS OF ONCOLOGY

Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation ofSmad4(Dpc4)Immunostaining With Pattern of Disease Progression

(2011) Christopher H. Crane et al.   JOURNAL OF CLINICAL ONCOLOGY

Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial

(2011) Patrick J. Loehrer et al.   JOURNAL OF CLINICAL ONCOLOGY

Lost in migration

(2010) George S Mack et al.   NATURE BIOTECHNOLOGY

The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy

(2009) Salvatore Ulisse et al.   CURRENT CANCER DRUG TARGETS

DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer

(2009) Christine A. Iacobuzio-Donahue et al.   JOURNAL OF CLINICAL ONCOLOGY

The Oral Serine Protease Inhibitor WX-671 – First Experience in Patients with Advanced Head and Neck Carcinoma

(2008) Jens E. Meyer et al.   Breast Care